TDMS Study 88124-03 Pathology Tables
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
FINAL#1 CORE STUDY RATS
Facility: Battelle Northwest
Chemical CAS #: 22398-80-7
Lock Date: 09/25/98
Cage Range: All
Reasons For Removal: 25022 Accidently Killed 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 13 14 14 12
Natural Death 3 4 4
Accidently Killed 1
Survivors
Terminal Sacrifice 34 30 36 34
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (48) (48) (50) (48)
Polyp Adenomatous 1 (2%) 1 (2%)
Intestine Large, Rectum (49) (48) (50) (47)
Polyp Adenomatous 1 (2%)
Intestine Small, Ileum (47) (46) (50) (48)
Liver (50) (50) (50) (50)
Hepatocellular Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (9) (15) (15) (19)
Oral Mucosa (2) (2)
Gingival, Squamous Cell Carcinoma 1 (50%)
Pharyngeal, Squamous Cell Carcinoma 1 (50%)
Pharyngeal, Squamous Cell Papilloma 1 (50%)
Pancreas (50) (50) (50) (49)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (49)
Stomach, Glandular (49) (50) (50) (48)
Carcinoid Tumor Benign 1 (2%)
Tongue (1) (1) (1) (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Schwannoma Benign 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (50) (49)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Adrenal Medulla (50) (48) (50) (49)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 2 (4%) 6 (13%) 2 (4%) 7 (14%)
Bilateral, Pheochromocytoma Benign 2 (4%)
Islets, Pancreatic (50) (50) (50) (49)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (50) (50) (48) (49)
Pars Distalis, Adenoma 30 (60%) 27 (54%) 29 (60%) 25 (51%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (47) (47) (50) (47)
Bilateral, C-Cell, Adenoma 1 (2%) 1 (2%)
C-Cell, Adenoma 6 (13%) 6 (13%) 5 (10%) 1 (2%)
C-Cell, Carcinoma 3 (6%) 2 (4%) 2 (4%) 1 (2%)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (49) (47) (47) (49)
Adenoma 5 (10%) 4 (9%) 4 (9%) 6 (12%)
Carcinoma 1 (2%) 3 (6%)
Carcinoma, Multiple 1 (2%)
Bilateral, Carcinoma 1 (2%)
Ovary (50) (50) (50) (49)
Granulosa Cell Tumor Malignant 1 (2%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Granulosa-Theca Tumor Malignant 1 (2%)
Uterus (50) (50) (50) (49)
Leiomyosarcoma 1 (2%)
Polyp Stromal 10 (20%) 4 (8%) 10 (20%) 8 (16%)
Polyp Stromal, Multiple 2 (4%)
Sarcoma Stromal 1 (2%)
Schwannoma Malignant 1 (2%)
Vagina (1)
Leiomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (48)
Lymph Node (1) (5) (1) (2)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (100%)
Lymph Node, Bronchial (25) (30) (35) (30)
Lymph Node, Mandibular (43) (48) (42) (42)
Lymph Node, Mesenteric (50) (47) (50) (47)
Hemangiosarcoma 1 (2%)
Lymph Node, Mediastinal (28) (36) (39) (26)
Spleen (50) (50) (50) (47)
Thymus (45) (47) (50) (45)
Thymoma Benign 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Carcinoma 8 (16%) 3 (6%) 1 (2%)
Carcinoma, Multiple 1 (2%)
Fibroadenoma 16 (32%) 14 (28%) 16 (32%) 11 (22%)
Fibroadenoma, Multiple 4 (8%) 5 (10%) 2 (4%) 1 (2%)
Skin (50) (49) (50) (49)
Basal Cell Adenoma 1 (2%)
Keratoacanthoma 2 (4%)
Squamous Cell Carcinoma 1 (2%)
Sebaceous Gland, Carcinoma 1 (2%)
Subcutaneous Tissue, Fibroma 3 (6%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Oligodendroglioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (49) (50) (49)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 4 (8%) 18 (36%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%) 1 (2%) 4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 7 (14%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Trachea (50) (49) (50) (49)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50) (48)
Lipoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (49) (49) (50) (49)
Transitional Epithelium, Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 14 (28%) 21 (42%) 14 (28%) 24 (48%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 47 48 46
Total Primary Neoplasms 107 120 111 133
Total Animals with Benign Neoplasms 44 39 44 40
Total Benign Neoplasms 80 78 83 90
Total Animals with Malignant Neoplasms 24 30 24 32
Total Malignant Neoplasms 27 42 28 43
Total Animals with Metastatic Neoplasms 1 2
Total Metastatic Neoplasm 1 5
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 20 18 16 15
Natural Death 3 3 5 9
Survivors
Terminal Sacrifice 27 29 29 26
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Squamous Cell Papilloma 1 (2%)
Intestine Large, Colon (50) (50) (47) (48)
Polyp Adenomatous 1 (2%)
Intestine Large, Cecum (48) (50) (46) (46)
Intestine Small, Duodenum (49) (50) (47) (48)
Intestine Small, Jejunum (48) (48) (46) (43)
Carcinoma 1 (2%)
Intestine Small, Ileum (47) (49) (46) (44)
Liver (50) (50) (50) (50)
Cholangiocarcinoma 1 (2%) 1 (2%)
Cholangioma 1 (2%)
Hepatocellular Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mesentery (6) (6) (6) (8)
Squamous Cell Carcinoma, Metastatic, Lung 1 (13%)
Oral Mucosa (1) (3) (2)
Gingival, Squamous Cell Papilloma 2 (67%)
Pharyngeal, Squamous Cell Papilloma 1 (100%) 1 (33%) 1 (50%)
Pancreas (50) (50) (50) (50)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Leiomyosarcoma 1 (2%)
Stomach, Glandular (50) (50) (48) (49)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Schwannoma Benign 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
Pericardium, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
Adrenal Medulla (50) (50) (49) (50)
Pheochromocytoma Malignant 3 (6%) 3 (6%) 1 (2%)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 10 (20%) 16 (32%) 12 (24%) 18 (36%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
Bilateral, Pheochromocytoma Benign 6 (12%) 4 (8%) 5 (10%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%) 2 (4%) 2 (4%) 3 (6%)
Carcinoma 2 (4%) 4 (8%) 3 (6%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
Parathyroid Gland (44) (44) (45) (45)
Adenoma 1 (2%)
Pituitary Gland (49) (50) (50) (50)
Pars Distalis, Adenoma 36 (73%) 33 (66%) 31 (62%) 30 (60%)
Pars Distalis, Carcinoma 1 (2%) 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (49) (48) (48)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 5 (10%) 7 (14%) 4 (8%) 9 (19%)
C-Cell, Carcinoma 1 (2%) 4 (8%) 3 (6%) 1 (2%)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1) (1)
Histiocytic Sarcoma 1 (100%)
Tissue NOS (1)
Chemodectoma Malignant 1 (100%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Preputial Gland (50) (50) (50) (50)
Adenoma 1 (2%) 2 (4%)
Carcinoma 2 (4%) 1 (2%)
Prostate (50) (50) (50) (50)
Adenoma 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Adenoma, Multiple 1 (2%)
Seminal Vesicle (50) (49) (48) (49)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Testes (50) (50) (50) (50)
Bilateral, Interstitial Cell, Adenoma 27 (54%) 25 (50%) 26 (52%) 17 (34%)
Interstitial Cell, Adenoma 13 (26%) 10 (20%) 15 (30%) 16 (32%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Lymph Node (2) (4) (2)
Renal, Squamous Cell Carcinoma, Metastatic,
Lung 1 (50%)
Lymph Node, Bronchial (26) (27) (41) (44)
Histiocytic Sarcoma 1 (4%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
Lymph Node, Mandibular (44) (42) (47) (47)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
Lymph Node, Mesenteric (50) (50) (49) (50)
Lymph Node, Mediastinal (25) (19) (45) (40)
Squamous Cell Carcinoma, Metastatic, Lung 2 (5%)
Spleen (50) (50) (49) (48)
Thymus (47) (47) (46) (45)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (24) (33) (31) (24)
Carcinoma 1 (3%) 1 (4%)
Fibroadenoma 2 (8%) 1 (3%) 1 (4%)
Skin (50) (50) (50) (49)
Histiocytic Sarcoma 1 (2%)
Keratoacanthoma 2 (4%) 3 (6%) 5 (10%) 2 (4%)
Keratoacanthoma, Multiple 1 (2%)
Squamous Cell Papilloma 1 (2%)
Trichoepithelioma 1 (2%)
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Sebaceous Gland, Adenoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 4 (8%) 7 (14%) 3 (6%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Liposarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Osteoma 1 (2%)
Osteosarcoma 3 (6%) 1 (2%) 1 (2%)
Skeletal Muscle (1)
Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Glioma Benign 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (50) (50)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 8 (16%) 19 (38%) 18 (36%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 5 (10%) 8 (16%) 12 (24%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 8 (16%) 7 (14%) 11 (22%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) 1 (2%) 5 (10%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 2 (4%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
Squamous Cell Carcinoma 4 (8%)
Mediastinum, Osteosarcoma, Metastatic, Bone 1 (2%)
Nose (50) (50) (50) (50)
Chondroma 1 (2%)
Esthesioneuroblastoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (2%)
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Pleura (2) (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%) 1 (50%)
Histiocytic Sarcoma 1 (50%)
Squamous Cell Carcinoma, Metastatic, Lung 1 (50%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1) (1)
Adenoma 1 (100%)
Carcinoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Liposarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Squamous Cell Carcinoma, Metastatic, Lung 2 (4%)
Urinary Bladder (50) (50) (49) (50)
Transitional Epithelium, Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%)
Leukemia Mononuclear 16 (32%) 23 (46%) 29 (58%) 25 (50%)
Mesothelioma Malignant 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 88124-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC INDIUM PHOSPHIDE Date: 10/28/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 14:01:46
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.03 0.1MG/M3 0.3MG/M3
MG/M3 STOP STOP
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 50 50 50
Total Primary Neoplasms 142 186 203 197
Total Animals with Benign Neoplasms 47 48 48 48
Total Benign Neoplasms 112 135 145 142
Total Animals with Malignant Neoplasms 26 37 42 37
Total Malignant Neoplasms 30 51 58 55
Total Animals with Metastatic Neoplasms 3 5 2 4
Total Metastatic Neoplasm 7 7 2 17
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 74250-74250/74250
--multipart-boundary--